Fighting the Zika virus

Fighting the Zika virus

Liverpool united with 25 research organisations to fight Zika virus.

The Institute of Infection and Global Health is among 25 leading research and public health organisations which gathered in Recife, Brazil for the launch of ZikaPLAN (Zika Preparedness Latin American Network).

This global initiative, created in response to a Horizon 2020 funding call by the European Commission’s Directorate-General Research and Innovation, was formed to address the Zika virus outbreak and the many research and public health challenges it poses.

The initiative takes a comprehensive approach to tackle the Zika threat by:

  • addressing the knowledge gaps and needs in the Zika outbreak to better understand the disease, prevent its spread and educate the affected populations,
  • building a sustainable response capacity in Latin America for Zika and other emerging infectious diseases (EID).

Liverpool’s role

Liverpool unites with 25 research organisations to fight Zika virus

As part of the ZikaPLAN consortium, the University has been working on improving the diagnosis of Zika, better understanding the neurological complications, and working towards vaccines and treatments.

ZikaPLAN has received a €11.5 million grant from the European Union’s Horizon 2020 research and innovation program, under grant agreement number 734584. €1.5 million of this has been awarded to the University of Liverpool.

Professor Tom Solomon, who is leading the University’s work said: “We have been working on Zika since the end of 2015, through support from the National Institute for Health Research and Medical Research Council. This additional funding will allow us to step up a gear, and establish longer term programmes with our colleagues in Brazil and Colombia.”

Dr Lance Turtle, who is leading the study of immune responses in Zika-linked neurological disease, added: “With a better understanding of how this virus damages the brain, and how the body’s immune system responds, we will be able to start developing vaccines.”

Back to: Research